Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephea Valve Technologies Inc.

cephea.com

Latest From Cephea Valve Technologies Inc.

Functional MR Added To FDA-Approved Indication For Abbott's MitraClip

The new indication covers functional mitral regurgitation, also known as secondary mitral regurgitation, which represents two-to-three times as many patients as the primary mitral regurgitation population MitraClip is already labeled for. The approval is supported by results from the COAPT trial, the first randomized trial to show that a mitral-valve repair could improve outcomes in patients with secondary mitral regurgitation.

Approvals Commercial

Abbott Advances Transcath Mitral Valve Efforts With Cephea Acquisition

Abbott has exercised an option to buy Cephea Valve Technologies, developer of a minimally-invasive replacement heart valve, for an undisclosed sum.

Cardiovascular M & A

Edwards Declares Victory In Transcatheter Mitral Valve Contract Suit

A jury recommended a $70m award to Edwards Lifesciences unit CardiAQ based on findings that another firm, Neovasc, breached a supplier contract and used CardiAQ's trade secrets to develop a competing transcatheter mitral valve device.

Medical Device Legal Issues

Millipede's Play In Percutaneous Mitral Valve Repair

As medtech strategics race to develop a percutaneously deliverable replacement mitral valve for patients with mitral regurgitation, start-ups tackle an array of mitral repair strategies. Building on a tried-and-true surgical approach, Millipede is developing a catheter-delivered adjustable annuloplasty ring that reduces annular dilation of the mitral valve in order to reduce or eliminate mitral regurgitation.

Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cephea Valve Technologies Inc.
  • Senior Management
  • Thierry Thaure, CEO
  • Contact Info
  • Cephea Valve Technologies Inc.
    Phone: (425) 208-5503
    3050 Three Springs Ct.
    San Jose, CA 95140
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register